INVESTORS CAREERS RESOURCES The Composition of the Board of Directors and its Committees meets the requirements of the Euronext code for the independence of directors. Philippe Genne Chairman and CEO After gaining a PhD in pharmacology from the University of Dijon, Philippe Genne began his scientific career as a project leader at Debiopharm where he oversaw a clinical development program related to multi-drug resistance inhibitors. He also worked as a research associate at Glaxo-Welcome. His preclinical research experience in oncology also encompasses phase I and phase II clinical trials in conjunction with Inserm. In 1995, he founded Oncodesign in Dijon. Over the past 18 years, he has earned a reputation as a serial entrepreneur in life sciences. As well as being Chairman of Oncodesign, a company specialized in the discovery of new therapies and European leader in the preclinical evaluation of anti-cancer therapies, he is also Chairman of the Pharmimage platform, which he set up in 2008. Philippe Genne is well known for his activities right across the life sciences value chain. In 2012, he helped set up the French association of life sciences service and innovation companies (AFSSI). He is the Vice-President of the SMEs College at Medicen. Jan Hoflack General Manager | Chief Scientific Officer | Head of Biotech Business Unit Jan Hoflack obtained a PhD in organic chemistry from the University of Ghent in Belgium before gaining solid experience and taking on executive positions at Marion Merrell Dow in Strasbourg (France), Novartis in Basel (Switzerland) and AstraZeneca in Gothenburg (Sweden). He was then appointed Vice President, Medicinal Chemistry and Biosciences at Johnson and Johnson Pharmaceutical R&D (Janssen) in Beerse (Belgium). He joined Oncodesign in 2009 as a partner and Chief Scientific Officer and was tasked with Setting up and developing full Drug Discovery capability. Drawing on his 31 years of R&D experience, including 22 years in the pharmaceutical industry, Jan invented the Nanocyclix chemistry technology that has provided access to next-generation kinase inhibitors. Explore the Biotech BU Fabrice Viviani General Manager | SEVP | Head of Service Business Unit Fabrice Viviani holds a PhD in organic chemistry and an MA in biology from Pierre-and-Marie-Curie University (UPMC). He started his career as a biologist and was responsible for research project and clinical teams in infectiology, before turning his attention to oncology research at Aventis’ oncology therapy department. He was then appointed Sanofi-Aventis’ Vice President for R&D, having managed several departments (medicinal chemistry and biology for exploratory research and internal medicine, early-to-candidate DPU). At GSK he took charge of the discovery biology group at the François Hyafil research center. To date, he has been involved in discovering and developing over 20 preclinical and clinical drug candidates. Explore the Service BU Stéphane GERART Chief Information Officer | Head of Artificial Intelligence Business Unit Stéphane Gerart is an engineer from the Ecole Polytechnique and the INA-PG and holds a PhD in immunology from Paris Descartes University. He begins his career as a business development consultant within the Consulting Firm Novoptim, a partner of choice in the strategic, marketing and operational support of fast-growing health life sciences companies on the European market. He then joins SOPHiA GENETICS in Canada. His mission as the country business development manager of this pioneer company in its field allowed him to acquire expertise in artificial intelligence and related applications. Back in France, as head of corporate business development for SOPHiA GENETICS, he is exposed to the booming ecosystem of new technologies in the healthcare world. He joins Oncodesign in 2020 to be responsible of the Artificial Intelligence Business Unit. Explore the AI BU Thierry Billoué Chief Human Resources Officer Thierry Billoué has over 20 years’ professional experience to his name and has worked in a variety of business sectors, including automotive, consumer electronics, IT services and IT security. He has supported mid-sized businesses (60 – 750 employees, revenue of €10 million-€150 million) pursuing a strategy of far-reaching transformation (exponential growth, business creation, turnaround phase, etc.). Today Thierry has responsibility for the organizational and human resources aspects of Oncodesign’s transformation as part of its development and growth strategy. He believes that all organizations, and all employees, are capable of transforming themselves and embracing change provided that they understand the reasons behind it, so that they strive for and effect this change themselves.” Explore our Talents Arnaud Lafforgue Chief Financial and Administrative Officer Arnaud Lafforgue has close to 20 years’ experience in consulting and management roles in both financial and operational functions. During his past nine years with Grant Thornton, his duties have included being Head of Transaction Services responsible for the Operational Deal Services offering. In this role, he supported various businesses and investment funds with their divestments, acquisitions, reorganizations and post-acquisition integrations. He also led a number of information system overhaul projects and complex reorganization projects in France and further afield – including in Morocco and the United Kingdom. Arnaud Lafforgue graduated from the EM-Lyon business school and holds a master’s degree in management from the University of Paris X. His career began as an organizational consultant with Arthur Andersen, and he then joined Kroll Talbot Hughes, a specialist in operational and financial corporate restructuring. Explore all our financial news Karine Lignel Senior Executive Vice President – Group Chief Development Officer Karine Lignel is an Agro-Food Engineer (ENSIA). She holds a Master’s degree in Finance and Management (IGIA). She started her career in the food industry where she held technical and management positions. She has been working in R&D, production, quality and innovation for 7 years at Barry-Callebaut. At the age of 25, she was in charge of a chocolate production plant staffed with 50 employees. In 2000, Karine Lignel switched to Venture Capital. This job, which she had exercised for more than 20 years, allowed her to continue to use her scientific knowledge while sharpening her analytical, financial and, above all, coaching skills. This role of support in growth and sustainability is one of the fundamental pillars of the financial shareholder: it guides and influences the governance bodies in their strategic decisions (commercial, acquisition, management). These decisions are generally supported by financing. Karine Lignel has accompanied more than sixty technology companies, mostly in the health industry, and has been a member of more than thirty boards (of directors or supervisory boards). In particular, she has assisted the IPO of Nanobiotix, Oncodesign and Medincell. Since 2008, Karine Lignel has been accompanying Oncodesign as a representative of “Crédit Mutuel Innovation”. Her various and complementary skills will help support and expand the company’s growth. Explore Homing Program Contact-us 18 rue Jean Mazen - FR - 21000 Dijon Tel.+33 380 788 260 Get in touch Science within easy reach! Receive our general letter or our financial news! Explore Oncodesign's vitality Legal notice Personal data policy